The potent calcitonin gene-related peptide receptor antagonist, telcagepant, does not affect nitroglycerin-induced vasodilation in healthy men

British Journal of Clinical Pharmacology

Volumn 71, Issue 5, 2011, Pages 708-717

  Van der Schueren, Bart J ^a   Blanchard, Rebecca ^b   Murphy, M Gail ^b   Palcza, John ^b   De Lepeleire, Inge ^c   Van Hecken, Anne ^a   Depré, Marleen ^a   de Hoon, Jan N ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b MERCK RESEARCH LABORATORIES   (United States)

^c MSD Europe Inc   (Belgium)

Author keywords

Augmentation index; Calcitonin gene related peptide; Cardiovascular safety; Echo tracking; Migraine therapy

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; PLACEBO; TELCAGEPANT;

ADULT; AORTIC AUGMENTATION INDEX; ARTICLE; BLOOD PRESSURE MEASUREMENT; BRACHIAL ARTERY DIAMETER; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HEMODYNAMICS; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VASODILATATION;

ADULT; AORTA; AZEPINES; BLOOD PRESSURE; BRACHIAL ARTERY; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; HEART RATE; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; NITROGLYCERIN; RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE; VASODILATION; VASODILATOR AGENTS; YOUNG ADULT;

EID: 79953840319     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2010.03869.x     Document Type: Article

References (51)

1. Humphrey PPA, Feniuk W. Mode of action of the anti-migraine drug sumatriptan. Trends Pharmacol Sci 1991; 12: 444-6.
2. Dodick DW, Martin VT, Smith T, Silberstein S. Cardiovascular tolerability and safety of triptans: a review of clinical data. Headache 2004; 44 (Suppl. 1): S20-30.
3. Goadsby PJ, Lipton RB, Ferrari MD. Migraine - current understanding and treatment. N Engl J Med 2002; 346: 257-70.
4. Buzzi MG, Bonamini M, Moskowitz MA. Neurogenic model of migraine. Cephalalgia 1995; 15: 277-80.
5. Edvinsson L. CGRP-receptor antagonism in migraine treatment. Lancet 2008; 372: 2089-90.
6. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990; 28: 183-7.
7. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993; 33: 48-56.
8. Adwanikar H, Ji G, Li W, Doods H, Willis WD, Neugebauer V. Spinal CGRP1 receptors contribute to supraspinally organized pain behavior and pain-related sensitization of amygdala neurons. Pain 2007; 132: 53-66.
9. Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, Pollentier S, Lesko LM. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004; 350: 1104-10.
10. Ho TW, Mannix LK, Fan X, Assaid C, Furtek C, Jones CJ, Lines CR, Rapoport AM. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 2008; 70: 1304-12.
11. Eftekhari S, Salvatore CA, Calamari A, Kane SA, Tajti J, Edvinsson L. Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion. Neuroscience 2010; 169: 683-96.
12. Edvinsson L, Linde M. New drugs in migraine treatment and prophylaxis: telcagepant and topiramate. Lancet 2010; 376: 645-55.
13. Vanmolkot FH, Van der Schueren BJ, de Hoon JN. Calcitonin gene-related peptide-induced vasodilation in the human forearm is antagonized by CGRP8-37: evaluation of a human in vivo pharmacodynamic model. Clin Pharmacol Ther 2006; 79: 263-73.
14. Van der Schueren BJ, Rogiers A, Vanmolkot FH, Van Hecken A, Depre M, Kane SA, De Lepeleire I, Sinclair SR, de Hoon JN. Calcitonin gene-related peptide8-37 antagonizes capsaicin-induced vasodilation in the skin: evaluation of a human in vivo pharmacodynamic model. J Pharmacol Exp Ther 2008; 325: 248-55.
15. Petersen KA, Birk S, Lassen LH, Kruuse C, Jonassen O, Lesko L, Olesen J. The CGRP-antagonist, BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers. Cephalalgia 2005; 25: 139-47.
16. Verheggen R, Bumann K, Kaumann AJ. BIBN4096BS is a potent competitive antagonist of the relaxant effects of alpha-CGRP on human temporal artery: comparison with CGRP(8-37). Br J Pharmacol 2002; 136: 120-6.
17. Wei EP, Moskowitz MA, Boccalini P, Kontos HA. Calcitonin gene-related peptide mediates nitroglycerin and sodium nitroprusside-induced vasodilation in feline cerebral arterioles. Circ Res 1992; 70: 1313-9.
18. Brain SD, Williams TJ, Tippins JR, Morris HR, MacIntyre I. Calcitonin gene-related peptide is a potent vasodilator. Nature 1985; 313: 54-6.
19. Ghatta S, O'Rourke ST. Nitroglycerin-induced release of calcitonin gene-related peptide from sensory nerves attenuates the development of nitrate tolerance. J Cardiovasc Pharmacol 2006; 47: 175-81.
20. Kruuse C, Iversen HK, Jansen-Olesen I, Edvinsson L, Olesen J. Calcitonin gene-related peptide (CGRP) levels during glyceryl trinitrate (GTN)-induced headache in healthy volunteers. Cephalalgia 2010; 30: 467-74.
21. Chan KY, Edvinsson L, Eftekhari S, Kimblad PO, Kane SA, Lynch J, Hargreaves RJ, de Vries R, Garrelds IM, van den Bogaerdt AJ, Danser AH, Maassenvandenbrink A. Characterization of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) in human isolated coronary arteries. J Pharmacol Exp Ther 2010; 334: 746-52.
22. You JP, Wang Q, Zhang W, Jansen-Olesen I, Paulson OB, Lassen NA, Edvinsson L. Hypercapnic vasodilatation in isolated rat basilar arteries is exerted via low pH and does not involve nitric oxide synthase stimulation or cyclic GMP production. Acta Physiol Scand 1994; 152: 391-7.
23. LiYJ, Du YH. CGRP-mediated cardiovascular effect of nitroglycerin. Med Hypotheses 2003; 60: 693-8.
24. Oliver JJ, Webb DJ. Noninvasive assessment of arterial stiffness and risk of atherosclerotic events. Arterioscler Thromb Vasc Biol 2003; 23: 554-66.
25. de Hoon JN, Willigers JM, Troost J, Struijker-Boudier HA, Van Bortel LM. Vascular effects of 5-HT1B/1D-receptor agonists in patients with migraine headaches. Clin Pharmacol Ther 2000; 68: 418-26.
26. Vanmolkot FH, de Hoon JN. Acute effects of sumatriptan on aortic blood pressure, stiffness, and pressure waveform. Clin Pharmacol Ther 2006; 80: 85-94.
27. Greig LD, Leslie SJ, Gibb FW, Tan S, Newby DE, Webb DJ. Comparative effects of glyceryl trinitrate and amyl nitrite on pulse wave reflection and augmentation index. Br J Clin Pharmacol 2005; 59: 265-70.
28. Oliver JJ, Bowler A, Beudeker Q, Cate T, Webb DJ. Dose-response relationship of sublingual nitroglycerin with brachial artery dilatation and change in central and peripheral augmentation index. Clin Pharmacol Ther 2005; 77: 337-8.
29. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Bull World Health Organ 2001; 79: 373-4.
30. Salvatore CA, Hershey JC, Corcoran HA, Fay JF, Johnston VK, Moore EL, Mosser SD, Burgey CS, Paone DV, Shaw AW, Graham SL, Vacca JP, Williams TM, Koblan KS, Kane SA. Pharmacological characterization of MK-0974 [N-[(3R, 6S)-6-(2, 3-difluorophenyl)-2-oxo-1-(2, 2, 2-trifluoroethyl)azepan-3- yl]-4-(2-oxo-2, 3-dihydro-1H-imidazo[4, 5-b]pyridin-1-yl)piperidine-1-carbox amide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine. J Pharmacol Exp Ther 2008; 324: 416-21.
31. El Assaad MA, Topouchian JA, Asmar RG. Evaluation of two devices for self-measurement of blood pressure according to the international protocol: the Omron M5-I and the Omron 705IT. Blood Press Monit 2003; 8: 127-33.
32. Gallagher D, Adji A, O'Rourke MF. Validation of the transfer function technique for generating central from peripheral upper limb pressure waveform. Am J Hypertens 2004; 17: 1059-67.
33. Wilkinson IB, Fuchs SA, Jansen IM, Spratt JC, Murray GD, Cockcroft JR, Webb DJ. Reproducibility of pulse wave velocity and augmentation index measured by pulse wave analysis. J Hypertens 1998; 16: 2079-84.
34. Hoeks APG, Brands PJ, Smeets FAM, Reneman RS. Assessment of the distensibility of superficial arteries. Ultrasound Med Biol 1990; 16: 121-28.
35. Kool MJF, van Merode T, Reneman RS, Hoeks APG, Struyker-Boudier HAJ, Van Bortel LMAB. Evaluation and reproducibility of a vessel wall movement detector system for assessment of large artery properties. Cardiovasc Res 1994; 28: 610-4.
36. Dishy V, Sofowora G, Harris PA, Kandcer M, Zhan F, Wood AJ, Stein CM. The effect of sildenafil on nitric oxide-mediated vasodilation in healthy men. Clin Pharmacol Ther 2001; 70: 270-9.
37. Booth BP, Tabrizi-Fard MA, Ho-Leung F. Calcitonin gene-related peptide-dependent vascular relaxation of rat aorta: an additional mechanism for nitroglycerin. Biochem Pharmacol 2000; 59: 1603-09.
38. de Hoon JN, Pickkers P, Smits P, Struijker-Boudier HA, Van Bortel LM. Calcitonin gene-related peptide: exploring its vasodilating mechanism of action in humans. Clin Pharmacol Ther 2003; 73: 312-21.
39. Davies JI, Struthers AD. Pulse wave analysis and pulse wave velocity: a critical review of their strengths and weaknesses. J Hypertens 2003; 21: 463-72.
40. Aksoy Y, Acikgoz N, Sivri N, Bariskaner E, Akturk E, Turhan H, Yetkin E. Decreased nitrate-mediated dilatation in patients with coronary artery ectasia: an ultrasonographic evaluation of brachial artery. Coron Artery Dis 2006; 17: 365-9.
41. Ho TW, Ferrari MD, Dodick DW, Galet V, Kost J, Fan X, Leibensperger H, Froman S, Assaid C, Koppen H, Winner P. Acute antimigraine efficacy and tolerability of the novel oral CGRP receptor antagonist MK-0974: a phase III clinical trial versus placebo and zolmitriptan. Headache 2008; 48: S7 (OR17).
42. Sinclair SR, Kane SA, Van der Schueren BJ, Xiao A, Willson KJ, Boyle J, de Lepeleire I, Xu Y, Hickey L, Denney WS, Li CC, Palcza J, Vanmolkot FH, Depre M, Van Hecken A, Murphy MG, Ho TW, de Hoon JN. Inhibition of capsaicin-induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK-0974). Br J Clin Pharmacol 2010; 69: 15-22.
43. Ho TW, Ferrari MD, Dodick DW, Galet V, Kost J, Fan X, Leibensperger H, Froman S, Assaid C, Lines C, Koppen H, Winner PK. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 2008; 372: 2115-23.
44. Edvinsson L, Ho TW. CGRP receptor antagonism and migraine. Neurotherapeutics 2010; 7: 164-75.
45. Bigal ME, Ho TW. Is there an inherent limit to acute migraine treatment efficacy? J Headache Pain 2009; 10: 393-4.
46. Connor KM, Shapiro RE, Diener HC, Lucas S, Kost J, Fan X, Fei K, Assaid C, Lines C, Ho TW. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology 2009; 73: 970-7.
47. Regan CP, Stump GL, Kane SA, Lynch JJ, Jr. Calcitonin gene-related peptide receptor antagonism does not affect the severity of myocardial ischemia during atrial pacing in dogs with coronary artery stenosis. J Pharmacol Exp Ther 2009; 328: 571-8.
48. Luo D, Deng PY, Ye F, Peng WJ, Deng HW, Li YJ. Delayed preconditioning by cardiac ischemia involves endogenous calcitonin gene-related peptide via the nitric oxide pathway. Eur J Pharmacol 2004; 502: 135-41.
49. Li D, Li NS, Chen QQ, Guo R, Xu PS, Deng HW, Li YJ. Calcitonin gene-related peptide-mediated cardioprotection of postconditioning in isolated rat hearts. Regul Pept 2008; 147: 4-8.
50. Behm MO, Blanchard RL, Murphy MG, Chodakewitz JA, Palcza JS, Harris DE, Butterfield KL, Smith WB, Haynes EM, Sackner-Bernstein J, Preston RA, Krucoff MW. Assessment of the effect of MK-0974, an oral CGRP receptor antagonist, on spontaneous ischemia in patients with stable cardiovascular disease. Headache 2008; 48: S39 (S1).
51. Vanmolkot FH, Van Bortel LM, de Hoon JN. Altered arterial function in migraine of recent onset. Neurology 2007; 68: 1563-70.